未登录

D

David Foster

university of south australia

H指数:34

被引数:5,283

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

KEY OUTCOMES OF THE VULVODYNIA SUMMIT: IDENTIFYING THERAPEUTIC OPTIONS FOR FURTHER RESEARCH STUDY IN THE TREATMENT OF PROVOKED VESTIBULODYNIA

外阴痛高峰论坛的关键成果：确定在诱发性阴蒂疼痛治疗中进一步研究治疗的疗法选择

JOURNAL OF SEXUAL MEDICINE

IF3.3

2025-04-250

PRE

Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis

类风湿关节炎患者甲氨蝶呤给药的药代动力学-药效学模型和模拟

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-07-050

OA

Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-07-284

OAAI

The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE

IF4.1

2022-07-2213

OAAI

Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients with Treatment-Refractory Depression

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-06-095

OAAI

Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE

IF4.1

2021-04-121

OAAI

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs

SCIENTIFIC REPORTS

IF3.9

2020-10-2927

OAAI

Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis

通过纵向暴露-反应分析证明固定剂量药物组合成分的贡献

IF3.7

2020-01-272

PREAI

Genetic Variance Estimates for Maize Yield, Grain Moisture, and Stalk Lodging for Doubled-Haploid and Conventional Selfed-Line Hybrids

IF4.1

2020-01-222

OAAI

Pharmacometrics in Australasia-Twenty Years of Population Approach Group of Australia and New Zealand

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2019-09-164

OAAI

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2019-02-279

OAAI

Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies

IF3.7

2017-04-2530

PREAI

Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-03-019

OA

Pharmacokinetic models of morphine and its metabolites in neonates: Systematic comparisons of models from the literature, and development of a new meta-model

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2016-09-0130

OAAI

A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption-Part I: Gastrointestinal pH

IF3.7

2016-08-05104

PREAI

A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time

IF3.7

2016-07-2031

PREAI

Limited fetal metabolism of rosiglitazone: Elimination via the maternal compartment in the pregnant ewe

罗格列酮的胎儿代谢受限: 通过怀孕母羊的母体隔室消除

REPRODUCTIVE TOXICOLOGY

IF2.8

2016-06-017

PREAI

Recruitment in a Clinical Trial of Provoked Vulvodynia and Evaluation of Racial Differences

OBSTETRICS AND GYNECOLOGY

IF4.7

2016-05-010

PREAI

Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug

PHARMACEUTICAL RESEARCH

IF4.3

2016-04-2727

PREAI

A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2016-04-070

OAAI